Skip to content
Assyro AI
FDA Orange Book · active-ingredient family

Simvastatin; sitagliptin phosphate

Simvastatin; sitagliptin phosphate: 1 brand, 0 generics; first approved Oct 07, 2011; on patent until Apr 11, 2026.

On patentHas discontinued products
Generic status & protection

Protected until Apr 11, 2026 (earliest listed patent expiry).

Earliest patent expiry
Brands (NDA)
1
Generics (ANDA)
0
Listed patents
2
Next patent expiry
Apr 11, 2026
4 mo ago

Brand (NDA) products

Originator applications
  • NDA 20234320126 strengths
    Approved strengths under this FDA application.
    StrengthDosage formRouteStatusTE
    10MG;EQ 100MG BASETABLETORALDiscontinued
    20MG;EQ 100MG BASETABLETORALDiscontinued
    40MG;EQ 100MG BASETABLETORALDiscontinued
    10MG;EQ 50MG BASETABLETORALDiscontinued
    20MG;EQ 50MG BASETABLETORALDiscontinued
    40MG;EQ 50MG BASETABLETORALDiscontinued

Patent & exclusivity timeline

Protection horizon
20262027TodayPatent 7326708: 2026-04-11Patent 7326708Patent 7326708*PED: 2026-10-11Patent 7326708*PED
Patent expiryExclusivity endToday

Listed patents

Orange Book patent file
Patents listed in the FDA Orange Book for this product, with expiration date and patent type.
PatentExpiresInType
73267084 mo ago
SubstanceProductU-1188
7326708*PEDin 2 mo

Approval history

FDA approval span
First approval
15 yr 1 mo ago
Most recent approval
14 yr 2 mo ago

Approvals span 2011–2012 across 1 FDA application.

Brand (NDA) 1100%
Generic (ANDA) 00%

Simvastatin; sitagliptin phosphate: frequently asked questions

Generics, reference-listed drug, patents, and exclusivity for this active ingredient, from the FDA Orange Book.

Built directly from the FDA Orange Book data file (products, patents, and exclusivity). TE codes, RLD/RS flags, patent expirations, and exclusivity dates match the official FDA record. Listed patents reflect those the NDA holder submits under 21 U.S.C. 355 and are not exhaustive.

Related FDA reference tools

Agent CTA Background

Your Next Submission Could Take 6+ Fewer Weeks and Cost $250K Less.